|
Baseline assessment
|
N = 56
|
N = 38
|
N = 110
| |
|
Demography
| | | | |
|
Female (n, %)
|
34 (59.6%)*
|
30 (78.9%)
|
91 (82.7%)
|
0.007
|
|
Age (years, IQR)
|
27 (20–39)#
|
42 (32–54)
|
39 (27–49)
|
< 0.001
|
|
Disease duration (months, IQR)
|
12 (3–56)
|
33 (4–72)
|
30 (4–120)
|
0.334
|
|
Clinical manifestation (n, %)
| | | | |
|
Systemic symptoms (fever, weakness, etc.)
|
15 (26.8%)
|
17 (44.7%)
|
45 (40.9%)
|
0.320
|
|
Neurological symptoms (headache, amaurosis, etc.)
|
17 (30.3%)
|
21 (55.3%)
|
51 (46.4%)
|
0.461
|
|
Cardiovascular symptoms (chest distress/pain, etc.)
|
10 (17.9%)#
|
16 (42.1%)
|
31 (28.2%)
|
0.010
|
|
Complications (n, %)
| | | | |
|
Renal insufficiency
|
5 (8.9%)#
|
1 (2.6%)&
|
12 (10.9%)
|
0.046
|
|
Heart failure
|
1 (1.8%)#, *
|
5 (13.2%)
|
18 (16.4%)
|
0.013
|
|
Cerebral infarction
|
1 (1.8%)*
|
0
|
8 (7.3%)
|
0.007
|
|
Hypertensive severity (n, %)
| | | | |
|
Moderate
|
18 (32.1%)
|
12 (31.6%)
|
32 (29.1%)
|
0.217
|
|
Severe
|
26 (46.4%)
|
10 (26.3%)&
|
58 (52.7%)
|
0.014
|
|
Artery involvement (n, %)
| | | | |
|
Renal artery stenosis > 75%
|
29 (51.8%)*
|
0
|
40 (36.4%)
|
< 0.001
|
|
Abdominal aorta stenosis > 50%
|
19 (33.9%)
|
0
|
24 (21.8%)
|
< 0.001
|
|
Echocardiography (n, %)
| | | | |
|
Severe AR
|
4 (7.1%)#
|
5 (11.4%)
|
10 (9.1%)
|
0.047
|
|
Follow-up assessment
|
N = 47
|
N = 35
|
N = 105
| |
|
Blood pressure control status (n, %)
| | | | |
|
Controlled
|
17 (36.2%)#
|
26 (74.3%)
|
52 (47.3%)
|
< 0.001
|
|
Improved
|
25 (53.2%)
|
7 (20.0%)
|
44 (40.0%)
|
0.117
|
|
Failure
|
5 (10.6%)#
|
2 (5.7%)
|
9 (8.2%)
|
0.032
|
|
Events (n, %)
| | | | |
|
Persistent refractory or malignant hypertension
|
9 (19.1%)#
|
3 (8.6%)&
|
15 (13.6%)
|
0.024
|
|
Renal insufficiency
|
4 (8.5%)
|
0
|
8 (7.3%)
|
0.178
|
|
Congestive heart failure
|
1 (2.1%)#
|
2 (5.7%)&
|
4 (3.8%)
|
0.017
|
|
Events free survival by the end
|
59.6%#
|
80.0%
|
67.6%
|
0.049
|
